Tricida Competitors

Phibro Animal Health (NASDAQ:PAHC) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Phibro Animal Health and Tricida's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations for Phibro Animal Health and Tricida, as provided by MarketBeat.

Phibro Animal Health presently has a consensus price target of $21.50, indicating a potential downside of 12.39%. Tricida has a consensus price target of $19.50, indicating a potential upside of 283.10%. Given Tricida's stronger consensus rating and higher probable upside, analysts clearly believe Tricida is more favorable than Phibro Animal Health.

Risk and Volatility

Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Tricida has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Institutional and Insider Ownership

50.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 70.5% of Tricida shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 70.4% of Tricida shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Phibro Animal Health and Tricida's top-line revenue, earnings per share and valuation.

Phibro Animal Health has higher revenue and earnings than Tricida. Tricida is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Phibro Animal Health beats Tricida on 7 of the 13 factors compared between the two stocks.

Enanta Pharmaceuticals (NASDAQ:ENTA) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Enanta Pharmaceuticals and Tricida's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations for Enanta Pharmaceuticals and Tricida, as provided by MarketBeat.

Enanta Pharmaceuticals presently has a consensus price target of $65.2857, indicating a potential upside of 33.92%. Tricida has a consensus price target of $19.50, indicating a potential upside of 283.10%. Given Tricida's higher probable upside, analysts clearly believe Tricida is more favorable than Enanta Pharmaceuticals.

Risk and Volatility

Enanta Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Tricida has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Institutional and Insider Ownership

90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.5% of Tricida shares are owned by institutional investors. 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 70.4% of Tricida shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Enanta Pharmaceuticals and Tricida's top-line revenue, earnings per share and valuation.

Enanta Pharmaceuticals has higher revenue and earnings than Tricida. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Summary

Enanta Pharmaceuticals beats Tricida on 8 of the 13 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Tricida (NASDAQ:TCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Arcturus Therapeutics and Tricida, as provided by MarketBeat.

Arcturus Therapeutics presently has a consensus price target of $70.6667, indicating a potential upside of 90.99%. Tricida has a consensus price target of $19.50, indicating a potential upside of 283.10%. Given Tricida's stronger consensus rating and higher probable upside, analysts clearly believe Tricida is more favorable than Arcturus Therapeutics.

Earnings & Valuation

This table compares Arcturus Therapeutics and Tricida's top-line revenue, earnings per share and valuation.

Arcturus Therapeutics has higher revenue and earnings than Tricida. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

74.3% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Tricida shares are owned by institutional investors. 12.6% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 70.4% of Tricida shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Arcturus Therapeutics and Tricida's net margins, return on equity and return on assets.

Risk and Volatility

Arcturus Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500. Comparatively, Tricida has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Tricida on 8 of the 13 factors compared between the two stocks.

Tricida (NASDAQ:TCDA) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Tricida and Akero Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

70.5% of Tricida shares are held by institutional investors. Comparatively, 83.5% of Akero Therapeutics shares are held by institutional investors. 70.4% of Tricida shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tricida and Akero Therapeutics' top-line revenue, earnings per share and valuation.

Akero Therapeutics is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Tricida and Akero Therapeutics, as provided by MarketBeat.com.

Tricida currently has a consensus price target of $19.50, indicating a potential upside of 283.10%. Akero Therapeutics has a consensus price target of $57.2857, indicating a potential upside of 106.36%. Given Tricida's higher probable upside, research analysts plainly believe Tricida is more favorable than Akero Therapeutics.

Volatility and Risk

Tricida has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.

Summary

Akero Therapeutics beats Tricida on 7 of the 11 factors compared between the two stocks.

Tricida (NASDAQ:TCDA) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Profitability

This table compares Tricida and ESSA Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

70.5% of Tricida shares are held by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are held by institutional investors. 70.4% of Tricida shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Tricida and ESSA Pharma's gross revenue, earnings per share (EPS) and valuation.

ESSA Pharma is trading at a lower price-to-earnings ratio than Tricida, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tricida and ESSA Pharma, as reported by MarketBeat.

Tricida currently has a consensus target price of $19.50, indicating a potential upside of 283.10%. ESSA Pharma has a consensus target price of $28.80, indicating a potential upside of 1.52%. Given Tricida's higher probable upside, equities analysts plainly believe Tricida is more favorable than ESSA Pharma.

Volatility & Risk

Tricida has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500.

Summary

ESSA Pharma beats Tricida on 7 of the 11 factors compared between the two stocks.

Tricida (NASDAQ:TCDA) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tricida and Annexon, as reported by MarketBeat.

Tricida currently has a consensus target price of $19.50, indicating a potential upside of 283.10%. Annexon has a consensus target price of $34.3333, indicating a potential upside of 37.72%. Given Tricida's higher probable upside, equities analysts plainly believe Tricida is more favorable than Annexon.

Profitability

This table compares Tricida and Annexon's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Tricida and Annexon's gross revenue, earnings per share (EPS) and valuation.

Institutional & Insider Ownership

70.5% of Tricida shares are held by institutional investors. Comparatively, 91.2% of Annexon shares are held by institutional investors. 70.4% of Tricida shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Annexon beats Tricida on 5 of the 8 factors compared between the two stocks.